$CNC

Centene: Q3 Earnings Snapshot

Centene Corp. (CNC) reported a Q3 loss of $71M, or 14 cents per share, but adjusted earnings of 58 cents per share beat estimates. Revenue was $50.65B, also exceeding forecasts. The company expects full-year revenue between $196.5B and $200.5B.

Original reporting
Published Oct 27, 2026, 10:10 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 27, 2026, 10:20 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Centene: Q3 Earnings Snapshot — source image
Decision brief

The 30-second read

$CNCBullishHigh
01

Why it matters

The earnings beat may provide a short‑term catalyst for the stock, while the loss underscores ongoing margin challenges.

02

Market read

First‑report earnings data for a large‑cap insurer; could influence sector sentiment and short‑term price action.

03

What to watch

Potential concerns about underlying cost pressures and future guidance not detailed in the release.

Relevance 8/10Novelty 8/10Timing: after‑hours today

Background

Centene's Q3 earnings were released via an automated news feed, highlighting a loss but a beat on adjusted earnings and revenue.

Company-level read

Ticker impact

$CNCBullishHigh confidence
Context

Centene reported Q3 loss of $71M, EPS loss of 14¢ but adjusted earnings of 58¢ beat expectations; revenue $50.65B also beat forecasts.

Expected impact

potential modest upside as the market prices in the earnings beat

Evidence & confidence

The beat on key metrics for a large‑cap health insurer typically prompts short‑term buying pressure.

Market effects

May lift sentiment for the broader managed‑care and health‑insurance sector.

U.S. health‑care stocks could see slight gains in early trading.

Limited to U.S. markets; no immediate global ripple.

Counterpoint

The loss of $71M and negative headline EPS could trigger short‑term selling despite the beat.

Key entities

  • Centene Corp.

    U.S. health insurance provider.

Related articles

$CNCMedAI 8/10

What Centene (CNC) Said on Its Q3 Earnings Call

Centene (CNC) reported Q3 earnings, highlighting strong Medicare segment performance with a 93.8% HBR. The company raised its 2026 pre-tax margin forecast for PDP to mid-to-high 3% and expects Medicare Advantage break-even in 2026. Marketplace margins are improving, with a full-year 2026 pre-tax margin expected at the top of the 4.5%-5% range. Centene reduced debt to $15.0B and expects adjusted EPS growth in 2027.

$CNCHighAI 8/10

Centene (CNC) Q3 2026 Earnings Call Transcript

Centene (CNC) reported Q3 2026 earnings, highlighting a Medicaid HBR of 93.6, up 30 basis points from Q2. The company expects full-year Medicaid HBR of 93.5. Medicaid membership was in line with expectations, with a projected 8-9% year-end decline. Medicare Advantage and standalone Part D performed well, with Medicare Advantage on track for 2026 breakeven. Marketplace business is expected to produce a full-year pretax margin at the top of the 4.5% to 5.0% range.

$CNCMed

Centene Corporation Q3 2026 Earnings Call Summary

Centene Corporation reported Q3 2026 earnings, highlighting Medicare Advantage breakeven, Medicaid stability, and Marketplace margin recovery. The company reduced debt to $15.0 billion and expects 2027 adjusted EPS growth. Management plans to exit less profitable areas and optimize costs. Medicaid membership is declining, and Marketplace enrollment may contract in 2027. Non-recurring benefits added $0.50 per share in 2026.

$CNCMed

Centene progresses on profit recovery, drops 6,000 employees

Centene reported Q3 revenue of $50.6B, up 2% YoY, and narrowed losses to $71M. The company raised its 2026 earnings outlook due to Medicare Advantage cost reductions, now expecting to break even in the segment. Centene also announced layoffs and voluntary separations, reducing its workforce by 6,000 employees, which is expected to improve margins in 2027. The company's medical loss ratio was 92.7%, slightly better than expected.